







an Open Access Journal by MDPI

## **Natural Products from Marine Bacteria 2024**

Guest Editors:

### **Dr. Christopher Cartmell**

Department of Pharmacology, College of Medicine, Comprehensive Pain and Addiction Center, University of Arizona, Tucson, AZ, USA

### Prof. Dr. Robert John Capon

Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia

Deadline for manuscript submissions:

closed (30 April 2024)

# **Message from the Guest Editors**

Dear Colleagues,

This Special Issue of *Marine drugs* is titled "Natural Products from Marine Bacteria". The aim of this Special Issue is to capture the ongoing efforts of a wide range of researchers within the marine natural product field.

The scope of the following Issue includes, but is not limited to, the following:

- Classic marine microbial natural product discovery;
- Marine microbial biotechnological developments for drug discovery;
- Natural products probing marine host–symbiont interactions;
- Marine microbial metagenomics for natural product discovery;
- Synthesis of natural products of marine microbial origin;
- Analogue generation of natural products of marine microbial origin.

Dr. Christopher Cartmell Prof. Dr. Robert John Capon Guest Editors













an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

# **Message from the Editor-in-Chief**

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

#### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmacology, Toxicology and Pharmaceutics (miscellaneous)*)

#### **Contact Us**